HEADLINES: • Banca Transilvania: bottom-line beat in 3Q25, on higher trading income and lower costs POSITIVE • Jahez: 3Q25 financial results review NEGATIVE • Pegasus Airlines: 3Q25 – RASK pressure exceeds our estimate NEGATIVE • CCC: preliminary 3Q25 EBITDA miss of 5%; FY25E EBITDA guidance cut to PLN 1.7-1.8bn, from PLN 2.4bn NEGATIVE • Alpha Bank: 3Q25 highlights – a mixed bag NEUTRAL • Dino: key takeaways from the 3Q25 call NEGATIVE • InPost: key takeaways from the 3Q25 call NEGATIVE • MOL: ...
With the gain of Brazilian contracts, Voltalia has surpassed 8 gigawatts of capacity under management for third parties, reaching its 2027 target two years ahead of schedule With the gain of Brazilian contracts, Voltalia has surpassed 8 gigawatts of capacity under management for third parties, reaching its 2027 target two years ahead of schedule Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, announces the signing of 937 megawatts of new maintenance contracts in Brazil. With these agreements, the capacity operated on be...
Avec le gain de contrats brésiliens, Voltalia franchit le cap des 8 gigawatts de capacité en exploitation pour compte de tiers, avec deux ans d’avance sur son objectif 2027 Avec le gain de contrats brésiliens, Voltalia franchit le cap des 8 gigawatts de capacité en exploitation pour compte de tiers, avec deux ans d’avance sur son objectif 2027 Voltalia (Euronext Paris, ISIN code : FR0011995588), acteur international des énergies renouvelables, annonce la signature de 937 mégawatts de nouveaux contrats de maintenance au Brésil. Grâce à ces accords, la capacité opérée pour compte de tiers ...
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT ...
EME Equity Market – October 2025 Hungarian BUX leads in October, Türkiye and Greece lag. The MSCI EM Europe Index added 3.5% mom in EUR terms and 1.8% mom in USD terms in October. The Hungarian BUX was the top performer, adding 9.1% mom in EUR terms; followed by the Polish WIG20 (+5.9% mom) and the Romanian BET (+5.4% mom) (in EUR terms). The Czech PX was also in the green (+2.8% mom in EUR terms). The Greek ASE and the Turkish ISE30 (-1.9% mom and -1.1% mom, in EUR terms, respectively) both los...
A director at Abivax sold 1,200,000 shares at 94.085EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.